POSTERIOR-FOSSA MEDULLOBLASTOMA IN CHILDHOOD - TREATMENT RESULTS ANDA PROPOSAL FOR A NEW STAGING SYSTEM

被引:101
作者
JENKIN, D
GODDARD, K
ARMSTRONG, D
BECKER, L
BERRY, M
CHAN, H
DOHERTY, M
GREENBERG, M
HENDRICK, B
HOFFMAN, H
HUMPHREYS, R
SONLEY, M
WEITZMAN, S
ZIPURSKY, A
机构
[1] HOSP SICK CHILDREN, DEPT RADIOL, LONDON WC1N 3JH, ENGLAND
[2] HOSP SICK CHILDREN, DEPT PATHOL, LONDON WC1N 3JH, ENGLAND
[3] HOSP SICK CHILDREN, DEPT NEUROSURG, LONDON WC1N 3JH, ENGLAND
[4] HOSP SICK CHILDREN, DEPT HEMATOL ONCOL, LONDON WC1N 3JH, ENGLAND
[5] PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1990年 / 19卷 / 02期
关键词
Childhood treatment; Medulloblastoma; Prognostic factors;
D O I
10.1016/0360-3016(90)90533-P
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Seventy-two children with posterior fossa medulloblastoma were diagnosed at the Hospital for Sick Children, Toronto, from 1977 to 1987 and treated by standard methods. The 5- and 10-year survival and disease-free survival rates were 71% and 63%, and 64% and 63%, respectively. Total tumor resection, as determined by the surgeon was the most significant favorable prognostic factor. Post-operative meningitis, a residual enhancing mass lesion on the post-operative, pre irradiation CT scan and dissemination to the brain or cord at diagnosis were unfavorable factors. These four easily definable factors were used to define a staging system with prognostic significance. Five-year disease-free survival rates were for Stage I (total resection, no adverse factor) 100%, Stage II (total resection with one or more adverse factor or less than total resection with no other adverse factor) 78%, and Stage III (less than total resection with one or more adverse factor) 18%. Evaluation of treatment results in medulloblastoma requires that these prognostic factors be known. © 1990.
引用
收藏
页码:265 / 274
页数:10
相关论文
共 28 条
[1]   MEDULLOBLASTOMA AND OTHER PRIMARY MALIGNANT NEUROECTODERMAL TUMORS OF THE CNS - THE EFFECT OF PATIENTS AGE AND EXTENT OF DISEASE ON PROGNOSIS [J].
ALLEN, JC ;
EPSTEIN, F .
JOURNAL OF NEUROSURGERY, 1982, 57 (04) :446-451
[2]  
BELLANI FF, 1984, CANCER, V54, P1956, DOI 10.1002/1097-0142(19841101)54:9<1956::AID-CNCR2820540928>3.0.CO
[3]  
2-J
[4]   RADIATION TREATMENT FOR MEDULLOBLASTOMA - A 21-YEAR REVIEW [J].
BERRY, MP ;
DEREK, R ;
JENKIN, T ;
KEEN, CW ;
NAIR, BD ;
SIMPSON, WJ .
JOURNAL OF NEUROSURGERY, 1981, 55 (01) :43-51
[5]   LONG-TERM RESULTS OF A PILOT-STUDY OF LOW-DOSE CRANIAL-SPINAL IRRADIATION FOR CEREBELLAR MEDULLOBLASTOMA [J].
BRAND, WN ;
SCHNEIDER, PA ;
TOKARS, RP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (11) :1641-1645
[6]   A REVIEW OF THE FACTORS INFLUENCING THE PROGNOSIS OF MEDULLOBLASTOMA - THE IMPORTANCE OF CELL-DIFFERENTIATION [J].
CAPUTY, AJ ;
MCCULLOUGH, DC ;
MANZ, HJ ;
PATTERSON, K ;
HAMMOCK, MK .
JOURNAL OF NEUROSURGERY, 1987, 66 (01) :80-87
[7]   AN OPERATIVE STAGING SYSTEM AND A MEGAVOLTAGE RADIOTHERAPEUTIC TECHNIC FOR CEREBELLAR MEDULLOBLASTOMAS [J].
CHANG, CH ;
HOUSEPIAN, EM ;
HERBERT, C .
RADIOLOGY, 1969, 93 (06) :1351-+
[8]  
CHOUX M, 1982, NEUROCHIRURGIE S, V28, P11
[9]  
Cox DR, 1984, ANAL SURVIVAL DATA, pviii
[10]  
DEUTSCH M, 1980, CANCER, V45, P2194, DOI 10.1002/1097-0142(19800415)45:8<2194::AID-CNCR2820450831>3.0.CO